| The Committee reviewed the Hepatitis C Agents class and unaminously approved adding Mavyret to the PDL at preferred status, moving Pegasys, Pegintron, Sovaldi, Technivie, Viekira Pak and Viekira XR to non-preferred status, and adding Vosevi to the PDL at non-preferred status. The Committee recognized the changing landscape within the Hepatitis C Agents class and identfied that the proposed PDL changes ensure access to cost-effective evidence-based treatment options for MA beneficiaries. |
“The Health Resources and Services Administration’s (HRSA) HIV/AIDS Bureau released its bi-annual Ryan White HIV/AIDS Program Highlights. The Philadelphia Department of Public Health’s “C Ya!” project, which aimed to reduce disparities related to HCV co-infection Read more…
“We believe Philadelphia can be the first city to eliminate Hep C – I believe that to my core. We need to be voting, we need to be asking our local government officials to provide Read more…
Former Black Panther and internationally renowned journalist Mumia Abu-Jamal spent 5 years fighting for access to hepatitis C treatment while in prison. On July 19, a federal appeals court upheld his right to sue Corrections Read more…